New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Genmab A/S Sponsored ADR (GMAB) vs Royalty Pharma PLC (RPRX)

Genmab A/S Sponsored ADR and Royalty Pharma PLC are both Biotechnology companies. Royalty Pharma PLC is the larger, with a market value of $38.9B against $31.5B — 1.2× the size. Genmab A/S Sponsored ADR trades at the lower P/E: 43.0× against 47.2×. Genmab A/S Sponsored ADR grew revenue faster over the last twelve months: 19.8% against 11.4%. Royalty Pharma PLC has the higher net margin (25.7% vs 17.0%) and the lower return on invested capital (5.24% vs 6.89%). Across the 21 metrics below, Genmab A/S Sponsored ADR leads on 13 and Royalty Pharma PLC on 8.

Valuation

Metric GMAB RPRX Biotechnology median
P/E 42.98 47.21 8.49
P/S 7.22 11.67 8.56
P/B 4.90 3.12 2.04
Price to free cash flow n/m 30.06 23.84
EV/EBITDA 29.78 25.19 0.69
EV/Sales 7.95 14.74 8.00
Earnings yield 2.33% 2.12% (35.81%)
Free cash flow yield (20.53%) 3.33% (25.41%)

Profitability

Metric GMAB RPRX Biotechnology median
Gross margin 92.60% 100.00% 70.18%
Operating margin 24.30% 57.14% 0.00%
Net margin 16.97% 25.70% 0.00%
Free cash flow margin (148.32%) 38.81% 0.00%
Return on equity 12.07% 6.93% (51.58%)
Return on assets 7.31% 3.47% (45.91%)
Return on invested capital 6.89% 5.24% 0.00%

Growth

Metric GMAB RPRX Biotechnology median
Revenue growth (TTM) 19.83% 11.36% 7.20%
EPS growth (last fiscal year) (12.50%) (6.81%) 29.04%
Revenue growth, 5-year CAGR 19.15% 2.30% 9.54%
Net income growth, 5-year CAGR 5.73% (4.59%) 0.00%

Health

Metric GMAB RPRX Biotechnology median
Debt to equity 0.79 0.88 0.00
Current ratio 2.45 1.29 4.79
Net debt to EBITDA 3.13 5.22 1.01

Dividend

Metric GMAB RPRX Biotechnology median
Dividend yield — 1.37% 0.41%
Payout ratio — 0.70 —

Size

Metric GMAB RPRX Biotechnology median
Market cap 31.54b 38.85b 150.57m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack